DALVANCE® (dalbavancin)

LENGTH OF AUTHORIZATION: UP TO TWO WEEKS

CLINICAL NOTES:
Dalbavancin is a second-generation glycopeptide antibiotic. It is approved for acute bacterial skin and skin structure infections caused by susceptible bacteria like *Staphylococcus aureus* (including methicillin-sensitive and methicillin-resistant strains) and *Streptococcus pyogenes*.

INITIAL REVIEW CRITERIA:
- Patient must be ≥ 18 years old AND
- Patient has been diagnosed with a bacterial skin/skin structure infection likely due to a gram positive organism (e.g. cellulitis or wound abscess). Dalvance is not indicated for use in other sites of infection such as urinary tract infections or pneumonia; AND
- Patient must have medical documentation of trial and failure of vancomycin for the current active infection or a culture and sensitivity report indicating the gram positive organism is resistant to vancomycin.

DOSSING & ADMINISTRATION:
- Single dose regimen: 1500mg IV over 30 minutes.
- Two dose regimen: 1000 mg IV one time then 500 mg IV one week later.
- Dosage Form: 500 mg powder for injection